CAR T-Cell Therapy for Multiple Myeloma
Cutting-Edge CAR T-Cell Therapy Approved for Multiple Myeloma Treatment
One of the most advanced cancer immunotherapies globally, CAR T-cell therapy is now available for multiple myeloma patients following FDA and Israeli health ministry approval
Multiple myeloma (MM) is a hematological malignancy that forms in a type of white blood cell called a plasma cell. Healthy plasma cells help you fight infections by producing antibodies that detect and attack germs. In multiple myeloma, cancerous plasma cells build up in the bone marrow and crowd out healthy blood cells. Rather than produce helpful antibodies, the cancer cells create abnormal proteins that can cause complications.
Common treatments for MM include chemotherapy, radiation therapy, targeted therapy, and bone marrow transplantation. While these can be effective for many patients, others, and especially those experiencing a relapse, many find them inadequate. Fortunately, following an FDA and Israeli health ministry approval, multiple myeloma patients can now benefit from CAR T-cell therapy, and cutting-edge immunotherapy, in select medical facilities.

Request a consultation
Sheba Medical Center provides innovative, personalized medical care to patients from around the world. We are the largest, most comprehensive hospital in the Middle East and dedicated to providing advanced and compassionate medicine for everyone.
We welcome all cases, including the rarest and the most challenging. Our medical teams collaborate to provide the best possible health outcomes. From your initial inquiry through the long-term follow-up care, we are here for you.
Request a consultation and a Sheba Case Manager will contact you shortly: